LLY
NEUTRAL
$958.65
Live
Eli Lilly and Company · NYSE
Target $1209.17
(+26.1%)
$623.78
52W Range
$1133.95
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$858.01B
P/E
41.7
ROE
101.2%
Profit margin
31.7%
Debt/Equity
1.65
Dividend yield
0.68%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Key Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Key Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)
AI Fair Value Estimate
Based on comprehensive analysis
$678.2
-29.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
45
Moderate
35
65
70
30
25
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Key drivers: Strong profitability (31.7% margin), Strong revenue growth of 42.6%, High valuation with P/E of 41.7
Confidence
55%
Value
35/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Premium 41.7x trailing earnings multiple.
- Trades above Graham Number.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 42.6%.
Watchpoints
No urgent risks highlighted.
Past
70/100
Historical performance + price trend: Shares moved +444.3% over 5Y and +20.0% over 1Y.
Positives
- ROE sits at 101.2%.
- Healthy profit margin of 31.7%.
Watchpoints
No urgent risks highlighted.
Health
30/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
25/100
Dividend policy fallback.
Positives
- Yield: 0.7%.
Watchpoints
- Weak dividend profile (Score: 25/100).
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$958.65
Analyst Target
$1209.17
Upside/Downside
+26.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LLY and closest competitors.
Updated 2026-04-01
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LLY
Eli Lilly and Company
Primary
|
+444.3% | +179.6% | +20.0% | +16.6% | -5.8% | +4.7% |
|
JNJ
Johnson & Johnson
Peer
|
+71.3% | +56.9% | +58.5% | +26.1% | -1.5% | -1.2% |
|
ABBV
AbbVie Inc.
Peer
|
+140.3% | +65.5% | +32.8% | +17.0% | -3.9% | +2.3% |
|
MRK
Merck & Co., Inc.
Peer
|
+93.0% | +22.1% | +44.3% | +36.7% | +0.6% | +1.6% |
|
UNH
UnitedHealth Group Incorporated
Peer
|
-11.6% | -29.1% | -21.8% | -10.0% | +17.4% | +3.4% |
LLY
Eli Lilly and Company
Primary
5Y
+444.3%
3Y
+179.6%
1Y
+20.0%
6M
+16.6%
1M
-5.8%
1W
+4.7%
JNJ
Johnson & Johnson
Peer
5Y
+71.3%
3Y
+56.9%
1Y
+58.5%
6M
+26.1%
1M
-1.5%
1W
-1.2%
ABB
AbbVie Inc.
Peer
5Y
+140.3%
3Y
+65.5%
1Y
+32.8%
6M
+17.0%
1M
-3.9%
1W
+2.3%
MRK
Merck & Co., Inc.
Peer
5Y
+93.0%
3Y
+22.1%
1Y
+44.3%
6M
+36.7%
1M
+0.6%
1W
+1.6%
UNH
UnitedHealth Group Incorporated
Peer
5Y
-11.6%
3Y
-29.1%
1Y
-21.8%
6M
-10.0%
1M
+17.4%
1W
+3.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
41.7
Forward P/E
22.78
PEG Ratio
N/A
P/B Ratio
32.33
P/S Ratio
13.16
EV/Revenue
13.17
EV/EBITDA
27.08
Market Cap
$858.01B
Profitability
Profit margins and return metrics
Profit Margin
31.67%
Operating Margin
44.9%
Gross Margin
83.04%
ROE
101.16%
ROA
19.41%
Growth
Revenue and earnings growth rates
Revenue Growth
+42.6%
Earnings Growth
+51.4%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+50.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.65
High debt
Current Ratio
1.58
Good
Quick Ratio
0.78
Poor
Cash/Share
$8.14
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$19.3B
Gross Margin
82.5%
Op. Margin
46.6%
Net Margin
34.4%
Total Assets
$112.5B
Liabilities
$85.9B
Equity
$26.5B
Debt/Equity
3.24x
Operating CF
$3.2B
CapEx
$-3.0B
Free Cash Flow
$0.3B
FCF Yield
8%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-04
$7.54
+9.1% surprise
2025-10-30
$7.02
+19.1% surprise
2025-08-07
$6.31
+12.9% surprise
Healthcare Sector Comparison
Comparing LLY against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
41.7
This Stock
vs
75.44
Sector Avg
-44.7%
(Discount)
Return on Equity (ROE)
101.16%
This Stock
vs
-88.14%
Sector Avg
-214.8%
(Below Avg)
Profit Margin
31.67%
This Stock
vs
-16.28%
Sector Avg
-294.5%
(Weaker)
Debt to Equity
1.65
This Stock
vs
2.66
Sector Avg
-37.9%
(Less Debt)
Revenue Growth
42.6%
This Stock
vs
124.04%
Sector Avg
-65.7%
(Slower)
Current Ratio
1.58
This Stock
vs
4.47
Sector Avg
-64.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LLY
Eli Lilly and Company
|
NEUTRAL | $858.01B | 41.7 | 101.2% | 31.7% | $958.65 | |
|
JNJ
Johnson & Johnson
|
NEUTRAL | $573.46B | 21.55 | 35.0% | 28.5% | $237.96 | Compare |
|
ABBV
AbbVie Inc.
|
NEUTRAL | $387.52B | 163.63 | 138.0% | 4.0% | $219.26 | Compare |
|
MRK
Merck & Co., Inc.
|
NEUTRAL | $299.79B | 16.66 | 36.9% | 28.1% | $121.25 | Compare |
|
UNH
UnitedHealth Group Incorporated
|
NEUTRAL | $293.61B | 24.43 | 12.5% | 2.7% | $323.48 | Compare |
LLY
Eli Lilly and Company
NEUTRAL
Mkt Cap
$858.0B
P/E
41.7
ROE
101.2%
Price
$958.65
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-16 | ALVAREZ RALPH | Director | Stock Award | 12 | $12,416 |
| 2026-03-16 | FYRWALD J. ERIK | Director | Stock Award | 10 | $9,917 |
| 2026-03-16 | SULZBERGER GABRIELLE | Director | Stock Award | 5 | $4,958 |
| 2026-03-16 | LUCIANO JUAN R | Director | Stock Award | 16 | $15,917 |
| 2026-02-19 | DOZIER ERIC | Officer | Gift | 481 | - |
| 2026-02-17 | ALVAREZ RALPH | Director | Stock Award | 11 | $12,417 |
| 2026-02-17 | FYRWALD J. ERIK | Director | Stock Award | 9 | $9,917 |
| 2026-02-17 | SULZBERGER GABRIELLE | Director | Stock Award | 4 | $4,959 |
| 2026-02-17 | LUCIANO JUAN R | Director | Stock Award | 15 | $15,917 |
| 2026-02-13 | ZAKROWSKI DONALD A | Chief Financial Officer | Stock Award | 184 | - |
| 2026-02-13 | CUSTER KENNETH L | Officer | Stock Award | 207 | - |
| 2026-02-13 | BROWN ADRIANE S | Officer | Stock Award | 391 | - |
| 2026-02-13 | MONTARCE LUCAS E | Chief Financial Officer | Stock Award | 368 | - |
| 2026-02-09 | HAKIM ANAT | General Counsel | Stock Award | 8,277 | $8,647,694 |
| 2026-02-09 | SKOVRONSKY DANIEL | Officer | Stock Award | 15,547 | $16,242,385 |
ALVAREZ RALPH
Director
2026-03-16
12 shares
·
$12,416
FYRWALD J. ERIK
Director
2026-03-16
10 shares
·
$9,917
SULZBERGER GABRIELLE
Director
2026-03-16
5 shares
·
$4,958
LUCIANO JUAN R
Director
2026-03-16
16 shares
·
$15,917
DOZIER ERIC
Officer
2026-02-19
481 shares
ALVAREZ RALPH
Director
2026-02-17
11 shares
·
$12,417
FYRWALD J. ERIK
Director
2026-02-17
9 shares
·
$9,917
SULZBERGER GABRIELLE
Director
2026-02-17
4 shares
·
$4,959
LUCIANO JUAN R
Director
2026-02-17
15 shares
·
$15,917
ZAKROWSKI DONALD A
Chief Financial Officer
2026-02-13
184 shares
CUSTER KENNETH L
Officer
2026-02-13
207 shares
BROWN ADRIANE S
Officer
2026-02-13
391 shares
MONTARCE LUCAS E
Chief Financial Officer
2026-02-13
368 shares
HAKIM ANAT
General Counsel
2026-02-09
8,277 shares
·
$8,647,694
SKOVRONSKY DANIEL
Officer
2026-02-09
15,547 shares
·
$16,242,385
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
29 analysts
Guggenheim
2026-03-30
Buy
Buy
HSBC
2026-03-17
Hold
Reduce
RBC Capital
2026-02-25
Outperform
Barclays
2026-02-20
Overweight
Freedom Broker
2026-02-10
Hold
Buy
Deutsche Bank
2026-02-09
Buy
Buy
JP Morgan
2026-02-05
Overweight
Overweight
Cantor Fitzgerald
2026-02-05
Overweight
Overweight
Wells Fargo
2026-02-05
Overweight
Overweight
Morgan Stanley
2026-02-05
Overweight
Overweight
Past News Coverage
Recent headlines mentioning LLY from our newsroom.
Newest → oldest
No matching news yet.